# Novo's Sogroya® receives FDA approval as the first and only once-weekly, long-acting growth hormone for children with Turner Syndrome (TS)

- Source: PR Newswire M&A
- Published: 2026-11-20T16:47:00+00:00
- Category: Business
- Original: https://www.prnewswire.com/news-releases/novos-sogroya-receives-fda-approval-as-the-first-and-only-once-weekly-long-acting-growth-hormone-for-children-with-turner-syndrome-ts-302947192.html
- Canonical: https://groundlevelnews.com/story/novo-s-sogroya-receives-fda-approval-as-the-first-and-only-once-weekly-2d09f1/

Sogroya® is a once-weekly treatment option for appropriate children 2.5 and older, offering an alternative to once-daily therapy, which may help address the common challenge of non-adherence associated with daily injections1 Approval based on results from the pivotal REAL8 clinical trial...

_Ground Level News shows a short summary only; the full article and all rights belong to PR Newswire M&A._
